Abstract
Comprehensive data on transmission mitigation behaviors and SARS-CoV-2 infection and serostatus are needed from large, community-based cohorts to identify SARS-CoV-2 risk factors and impact of public health measures. From July 2020 to March 2021, ≈5,500 adults from the East Bay Area, California were followed over three data collection rounds. We estimated the prevalence of antibodies from SARS-CoV-2 infection and COVID-19 vaccination, and self-reported COVID-19 test positivity. Population-adjusted SARS-CoV-2 seroprevalence was low, increasing from 1.03% (95% CI: 0.50-1.96) in Round 1 (July-September 2020), to 1.37% (95% CI: 0.75-2.39) in Round 2 (October-December 2020), to 2.18% (95% CI: 1.48-3.17) in Round 3 (February-March 2021). Population-adjusted seroprevalence of COVID-19 vaccination was 21.64% (95% CI: 19.20-24.34) in Round 3. Despite >99% of participants reporting wearing masks, non-Whites, lower-income, and lower-educated individuals had the highest SARS-CoV-2 seroprevalence and lowest vaccination seroprevalence. Our results demonstrate that more effective policies are needed to address these disparities and inequities.
Competing Interest Statement
Joe Lewnard reports receipt of grants unrelated to this study from Pfizer and Merck, Sharpe & Dohme, and consulting fees from Pfizer, Merck, Sharpe & Dohme, VaxCyte, and Kaiser Permanente. All other authors declare no competing interests.
Funding Statement
This study was funded by grants from Open Philanthropy, Fast Grants, Mercatus Center, the UC Berkeley Innovative Genomics Institute, and the UC Berkeley Center for Population Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the University of California, Berkeley Committee on Protection of Human Subjects (Protocol #2020-03-13121).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
De-identified individual participant data that underlie the results reported in this article (text, tables, figures may be shared for up to 36 months following publication after investigators whose proposed use of the data has been approved by an independent review committee. For individual participant data analysis or meta-analysis, proposals should be directed to Lisa Barcellos (lbarcellos{at}berkeley.edu) and Lynn Hollyer (lhollyer{at}berkeley.edu). Requests will be reviewed by an independent review committee and the UC Berkeley Institutional Review Board. Data may be shared upon approval. Data requestors will need to sign a data access agreement.
